168 related articles for article (PubMed ID: 18000379)
21. Expression of aphidicolin-induced fragile sites and their relationship between genetic susceptibility in breast cancer, ovarian cancer, and non-small-cell lung cancer patients.
Dhillon VS; Husain SA; Ray GN
Teratog Carcinog Mutagen; 2003; Suppl 1():35-45. PubMed ID: 12616595
[TBL] [Abstract][Full Text] [Related]
22. Common fragile genes.
Matsuyama A; Croce CM; Huebner K
Eur J Histochem; 2004; 48(1):29-36. PubMed ID: 15145773
[TBL] [Abstract][Full Text] [Related]
23. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
24. Common fragile site FRA11G and rare fragile site FRA11B at 11q23.3 encompass distinct genomic regions.
Fechter A; Buettel I; Kuehnel E; Savelyeva L; Schwab M
Genes Chromosomes Cancer; 2007 Jan; 46(1):98-106. PubMed ID: 17063465
[TBL] [Abstract][Full Text] [Related]
25. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
26. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer.
Denison SR; Callahan G; Becker NA; Phillips LA; Smith DI
Genes Chromosomes Cancer; 2003 Sep; 38(1):40-52. PubMed ID: 12874785
[TBL] [Abstract][Full Text] [Related]
27. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
28. Biallelic deletion and loss of expression analysis of genes at FRA2G common fragile site in tumor-derived cell lines.
Limongi ZM; Curatolo A; Pelliccia F; Rocchi A
Cancer Genet Cytogenet; 2005 Sep; 161(2):181-6. PubMed ID: 16102592
[TBL] [Abstract][Full Text] [Related]
29. Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesis: a differential expression and functional analysis.
Chan QK; Ngan HY; Ip PP; Liu VW; Xue WC; Cheung AN
Carcinogenesis; 2009 Jan; 30(1):114-21. PubMed ID: 18796737
[TBL] [Abstract][Full Text] [Related]
30. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization.
Kresse SH; Ohnstad HO; Paulsen EB; Bjerkehagen B; Szuhai K; Serra M; Schaefer KL; Myklebost O; Meza-Zepeda LA
Genes Chromosomes Cancer; 2009 Aug; 48(8):679-93. PubMed ID: 19441093
[TBL] [Abstract][Full Text] [Related]
31. Common fragile site profiling in epithelial and erythroid cells reveals that most recurrent cancer deletions lie in fragile sites hosting large genes.
Le Tallec B; Millot GA; Blin ME; Brison O; Dutrillaux B; Debatisse M
Cell Rep; 2013 Aug; 4(3):420-8. PubMed ID: 23911288
[TBL] [Abstract][Full Text] [Related]
32. Molecular parameters of genome instability: roles of fragile genes at common fragile sites.
Pichiorri F; Ishii H; Okumura H; Trapasso F; Wang Y; Huebner K
J Cell Biochem; 2008 Aug; 104(5):1525-33. PubMed ID: 18393361
[TBL] [Abstract][Full Text] [Related]
33. Frequent inactivation of RUNX3 in endometrial carcinoma.
Yoshizaki T; Enomoto T; Fujita M; Ueda Y; Miyatake T; Fujiwara K; Miyake T; Kimura T; Yoshino K; Kimura T
Gynecol Oncol; 2008 Sep; 110(3):439-44. PubMed ID: 18572225
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional profiling of genes at the human common fragile site FRA1H in tumor-derived cell lines.
Pelliccia F; Curatolo A; Limongi ZM; Bosco N; Rocchi A
Cancer Genet Cytogenet; 2007 Oct; 178(2):144-50. PubMed ID: 17954271
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of decreased expression of six large common fragile site genes in oropharyngeal squamous cell carcinomas.
Gao G; Kasperbauer JL; Tombers NM; Cornell MD; Smith DI
Transl Oncol; 2014 Dec; 7(6):726-31. PubMed ID: 25500082
[TBL] [Abstract][Full Text] [Related]
36. Alterations in the common fragile site gene Parkin in ovarian and other cancers.
Denison SR; Wang F; Becker NA; Schüle B; Kock N; Phillips LA; Klein C; Smith DI
Oncogene; 2003 Nov; 22(51):8370-8. PubMed ID: 14614460
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
[TBL] [Abstract][Full Text] [Related]
38. Common fragile sites.
Glover TW
Cancer Lett; 2006 Jan; 232(1):4-12. PubMed ID: 16229941
[TBL] [Abstract][Full Text] [Related]
39. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
40. Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles.
Axelsen JB; Lotem J; Sachs L; Domany E
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13122-7. PubMed ID: 17664417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
